Tag: Tonmya

In August 2025, the U.S. Food and Drug Administration (FDA) approved Tonmya (sublingual cyclobenzaprine), the first new medication for fibromyalgia in over 15 years, offering renewed hope for millions affected by this chronic condition. This development marks a significant advancement in pharmacological treatment options, specifically targeting the non-restorative sleep that often accompanies the widespread pain of fibromyalgia.

Cyclobenzaprine, a widely used skeletal muscle relaxant, was associated with over 10 million prescriptions filled yearly, highlighting its role in managing muscle-related pain. It is primarily prescribed to relieve the pain and discomfort of muscle spasms associated with acute, painful musculoskeletal conditions. It is most effective when used for short-term treatment, typically for two to three weeks, as part of a comprehensive plan that includes rest and physical therapy.